Brief: Cingulate Announces Complete Enrollment In Human Formulation Study Of CTx-2103 For Treatment Of Anxiety Disorders
24/05/2022 11:53
May 24 (Reuters) - Cingulate Inc CING.O :
* CINGULATE ANNOUNCES COMPLETE ENROLLMENT IN HUMAN
FORMULATION
STUDY OF CTX-2103 FOR THE TREATMENT OF ANXIETY DISORDERS
* CINGULATE INC - RESULTS OF STUDY ARE EXPECTED IN JULY 2022
Source text for Eikon: ID:nGNXZ7s12
Further company coverage: CING.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)